# Clinical Trials Data KIT - Document 66

# Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients

## Clinical Trial: https://clinicaltrials.gov/study/NCT02083042

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patient receiving a kidney graft\n\* Recipient being CMV-seropositive prior transplantation and receiving a graft from either a CMV-seropositive or from a seronegative donor (intermediate risk groups, D+/R+; D-/R+,)\n\* Patient scheduled to follow the preemptive antiviral strategy with oral valganciclovir or intravenous ganciclovir after transplantation\n\* Patient receiving the standard triple immunosuppressive regimen (CNI, MMF/MPA or mTOR inhibitors, steroids), with or without induction therapy (except ATG) as start therapy after transplantation\n\* Male or female patient at least 18 years of age\n\* Written informed consent\n\nExclusion Criteria:\n\n\* Patient is scheduled for the optional visit 1, but requires ongoing treatment with a systemic immunosuppressive drug already prior to kidney transplantation (except induction therapy other than ATG)\n\* Patient receiving ATG as induction therapy\n\* Patient is known to be positive for HIV or suffering from chronic hepatitis infections\n\* Patient has significant uncontrolled concomitant infections or other unstable medical conditions before transplantation that could interfere with the study objectives\n\* Patient is unable to comply with the visit schedule in the protocol\n\* Patient has any form of substance abuse, psychiatric disorder or condition that, in the opinion of the investigator may invalidate communication with the investigator",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Kidney transplant recipients of intermediate risk groups for CMV serostatus (D+/R+; D-/R+), and scheduled for the preemptive antiviral strategy",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention anything about KIT gene mutations as either an inclusion or exclusion criterion. Therefore, having a KIT gene mutation \*doesn't automatically disqualify\* a patient. They would need to meet all other inclusion criteria and not meet any of the exclusion criteria to be eligible.